Day One Biopharmaceuticals' Proposed Sale Under Investigation by Kahn Swick & Foti

Kahn Swick & Foti, LLC is investigating the proposed sale of Day One Biopharmaceuticals to Servier, seeking to determine if the $21.50 per share consideration and process are adequate. The transaction is structured as a tender offer, with time potentially being of the essence. Shareholders who believe the consideration undervalues the company can contact KSF at 855-768-1857 or visit https://www.ksfcounsel.com/cases/nasdaqgs-dawn/ for more information.